Anti-matriptase Antibody Immunoconjugates for Selective Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers expressing matriptase, such as multiple myeloma and epithelial cancers, face challenges due to high cytotoxicity of antineoplastic agents like MMAE and MMAF when administered alone, necessitating the development of therapeutically effective antibody-based treatments that can selectively target and minimize toxicity to normal tissues.
Innovation Solution
The development of immunoconjugates comprising an anti-matriptase antibody conjugated with cytotoxic agents like MMAE, MMAF, and doxorubicin, which are selectively delivered to matriptase-expressing cancer cells, reducing toxicity to normal tissues and leveraging immunomodulatory agents like thalidomide to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents like MMAE and MMAF are administered alone, then potent anticancer activity is achieved, but high cytotoxicity to normal tissues occurs
Solution Approach 1:
An antibody component is introduced as an intermediary carrier to deliver the chemotherapeutic agent selectively to tumor cells. The antibody binds to matriptase antigens on cancer cells, directing the cytotoxic agent to the target site while sparing normal tissues, thus resolving the contradiction between anticancer efficacy and tissue toxicity
Solution Approach 2:
The chemotherapeutic agent is delivered with localized specificity to matriptase-expressing tumor cells through antibody targeting. The cytotoxic effect is concentrated at the tumor site where the antigen is present, while normal tissues lacking the target antigen remain unaffected, achieving local quality differentiation in drug action
2Object-affected harmful factors
If antibody-based treatments are developed to reduce toxicity, then selectivity to tumor cells improves, but treatment complexity increases
Solution Approach 1:
The antibody and chemotherapeutic agent are merged into a single conjugate molecule through chemical linkage. This combination allows the antibody's targeting capability and the chemotherapeutic agent's cytotoxic effect to work together as one integrated therapeutic entity, reducing the need for separate administration steps and simplifying the overall treatment protocol
Solution Approach 2:
The antibody component serves multiple functions: it acts as a targeting vehicle to locate tumor cells, as a delivery mechanism to transport the chemotherapeutic agent, and as a specific binder to ensure selective accumulation at the tumor site. This multi-functionality reduces the need for additional separate components in the treatment system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoconjugates effectively target and inhibit the growth of matriptase-expressing cancer cells with reduced toxicity to normal tissues, demonstrating potent anticancer activity in both in vitro and in vivo models, including synergistic effects with thalidomide, and show promise in treating various hematological and epithelial malignancies.
Implementation Method 1
anti-matriptase antibody conjugated with cytotoxic agents like MMAE, MMAF, and doxorubicin, which are selectively delivered to matriptase-expressing cancer cells
Implementation Method 2
The linker comprises a cleavable linking moiety, for example, a Val-Cit moiety, which is cleavable by Capthesin B
Data Source
AI summary
The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.